More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings (-28.6% Growth)
- Ratings (8.3 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (11/3/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 55.91M
Marketable securities 0
Proceeds from sale of RXi, received January 6, 2011
Receivable 224.7K
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable
Prepaid expenses and other current assets 1.34M
Total current assets 57.47M
Equipment and furnishings, net 1.99M
Goodwill 183.78K
Other assets 685.39K
Total assets 60.33M
Current liabilities:
Accounts payable 7.29M
Accrued expenses and other current liabilities 5.4M
Warrant liabilities 0
Total current liabilities 15.11M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 68.37K
Additional paid-in capital 419.31M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares)
Accumulated deficit -396.02M
Total stockholders' equity 23.36M
Total liabilities and stockholders' equity 60.33M